BIRC5 and glioblastoma: Glioblastoma cells exposed to temozolomide, a first-line chemotherapeutic agent in treating GBM shortly after tumor resection and pathological analysis, and cationic gemini surfactants carrying anti-survivin siRNA, yielded a significant decrease in cell viability compared to the use of temozolomide alone [93].